Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,262.56 89.32 0.55%
S&P 500 1,842.98 12.37 0.68%
NASDAQ 4,034.16 11.47 0.29%
Ticker Volume Price Price Delta
STOXX 50 3,125.21 33.69 1.09%
FTSE 100 6,571.83 30.22 0.46%
DAX 9,267.77 94.06 1.03%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

Elsevier Launches Web-Based Pathway Studio and Adds New Molecular Data from Its Biology Journals to Boost Early Discovery



 Elsevier Launches Web-Based Pathway Studio and Adds New Molecular Data from
            Its Biology Journals to Boost Early Discovery Research

  PR Newswire

  ROCKVILLE, Maryland, March 26, 2013

ROCKVILLE, Maryland, March 26, 2013 /PRNewswire/ --

   Biologists working in life sciences and pharmaceutical research now have
access via the Web to molecular data from Elsevier and from articles obtained
                        from other leading publishers

Elsevier , a world-leading provider of scientific, technical and medical
information products and services, today announced the launch of a web-based
version of Pathway Studio , a research solution for biologists. Additionally,
Pathway Studio now incorporates biological data from Elsevier's biology
journals in addition to journals obtained through collaboration with
third-party publishers. The addition of this data to Pathway Studio results in
a resource that is unparalleled in depth and coverage of molecular
interactions with supporting evidence. The new web-based version broadly
extends access to researchers to reveal new insights and to assist with
critical decision making.

"Currently, molecular facts are scattered in individual articles and
researchers must gather and integrate these to advance new discovery," said
Jaqui Mason, Product Development Director for Biology Products at Elsevier.
"Pathway Studio presents these facts in a graphical context to help
researchers assemble biological models that can be applied to target discovery
programs, identify potential diagnostics, and reposition drugs. The new
content included in Pathway Studio can expose a more complete picture in
biology, which reduces risk, increases efficiency, and ultimately improves
success rate whether it's bringing a new drug to market or exploring a
theory."

"Incorporation of facts from Elsevier's biology journals into Pathway Studio,
as well as building a pipeline of fresh data through our collaboration with
third-party publishers, enables us to deliver additional value to our
portfolio of solutions across biology, chemistry, and medicine in order to
better serve the needs of customers in early discovery and biology
researchers," said Mark van Mierle, Managing Director of Elsevier's Pharma and
Biotech Group. "Offering a web-based version of Pathway Studio has allowed us
to streamline common tasks and make the benefit of this content accessible to
a broader and more general user-base."

The new web-based Pathway Studio adds additional early discovery capability to
Elsevier's suite of life science information solutions which include Reaxys,
the leading chemistry discovery engine, PharmaPendium which supports
regulatory and safety activities, TargetInsights, a biological literature
search system for early discovery and Quosa, which automates literature
management workflows with applications in pharmacovigilance and medical
affairs. This suite effectively delivers complementary solutions spanning
early discovery, pre-clinical, clinical and post-launch workflows.

For more information, visit the new Pathway Studio website .

                                    # # #

About Pathway Studio

Pathway Studio is integrated data mining and visualization software with
high-quality, comprehensive knowledge bases produced by applying MedScan,
Elsevier's proprietary text-mining technology, to a large corpus of biological
literature. Pathway Studio allows organizations and researchers to rapidly
connect relevant biological facts and relationships, visualize these facts in
context, and integrate and interpret experimental data. Pathway Studio is used
for defining and testing in silico-based hypotheses across a wide range of
disciplines including mechanistic modeling of disease, drug action and
toxicity, target discovery and validation, biomarker discovery, cellular and
network pathway building, protein-protein interactions and many more.

Pathway Studio is offered in configurations that scale to support individual
researchers and global corporations with access to domain specific knowledge
bases and cartridges. For more information, visit the Pathway Studio website

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical
information products and services. The company works in partnership with the
global science and health communities to publish more than 2,000 journals,
including The Lancet and Cell , and close to 20,000 book titles, including
major reference works from Mosby and Saunders. Elsevier's online solutions
include ScienceDirect , Scopus , Reaxys , ClinicalKey and Mosby's Suite ,
which enhance the productivity of science and health professionals, and the
SciVal suite and MEDai's Pinpoint Review , which help research and health care
institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people
worldwide. The company is part of Reed Elsevier Group PLC , a world leading
provider of professional information solutions in the Science, Medical, Legal
and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and
Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London
Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact Liz Griffioen Elsevier +31-20-485-2247 l.griffioen@elsevier.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement